BioSpace News Archive

Assertio Holdings, Inc. announced that it closed its previously announced registered direct of common stock at a purchase price of $0.62 per share for gross proceeds of approximately $14.0 million.

Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that it has commenced an underwritten public offering of its common stock.

Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet ® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately.

KalVista Pharmaceuticals, Inc. announced that it intends to offer and sell 4,500,000 shares of its common stock in an underwritten public offering.

Q4 2020 net sales rise 36% CER to $571.2 million, exceeding outlook of ≥+32% CER, and adjusted diluted EPS grows 42% to $0.68 CER, exceeding outlook of ~$0.64-0.65 CER Full-year 2020 net sales increase 23% CER to $1.87 billion, exceeding outlook of ~+22% CER, and adjusted diluted EPS grows 52% to $2.17 CER, exceeding outlook of ~$2.13-2.14 CER

Exelixis, Inc. (Nasdaq: EXEL) will host an investor briefing to discuss data presented at the American Society of Clinical Oncology’s 2021 Genitourinary Cancers Symposium (ASCO GU 2021). The online-only event will be held on Saturday, February 13, 2021, beginning at 5:30 p.m. EST / 2:30 p.m. PST.

Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today that it has commenced an underwritten public offering of 2,500,000 shares of its common stock.

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended December 31, 2020 (“Q2 FY 2021”).

SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that it has commenced an underwritten public offering of 3,000,000 shares of common stock.

Precision Optics Corporation, Inc. (OTCQB: PEYE) (the “Company”) today announced that it has scheduled a conference call to discuss second quarter fiscal year 2021 financial results on Tuesday, February 16, 2021 at 5:00pm ET .